Business Description
Zealand Pharma AS
ISIN : DK0060257814
Compare
Compare
Traded in other countries / regions
ZEAL.Denmark0NZU.UKZLDPF.USA22Z.Germany IPO Date
2010-11-23Description
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 22.91 | |||||
| Equity-to-Asset | 0.93 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.61 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 47.49 | |||||
| Beneish M-Score | 0.9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 6.6 | |||||
| 3-Year EBITDA Growth Rate | 10.7 | |||||
| 3-Year EPS without NRI Growth Rate | 16.8 | |||||
| 3-Year FCF Growth Rate | 24.7 | |||||
| 3-Year Book Growth Rate | -4 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 97.14 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 66.31 | |||||
| 9-Day RSI | 61.01 | |||||
| 14-Day RSI | 56.28 | |||||
| 6-1 Month Momentum % | 23.53 | |||||
| 12-1 Month Momentum % | 152.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 35.57 | |||||
| Quick Ratio | 35.57 | |||||
| Cash Ratio | 34.74 | |||||
| Days Inventory | 77.23 | |||||
| Days Sales Outstanding | 121.22 | |||||
| Days Payable | 2600.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.6 | |||||
| Shareholder Yield % | -13.88 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 90.96 | |||||
| Operating Margin % | -196.87 | |||||
| Net Margin % | -193.49 | |||||
| FCF Margin % | -146.17 | |||||
| ROE % | -20.49 | |||||
| ROA % | -17.85 | |||||
| ROIC % | -114.45 | |||||
| 3-Year ROIIC % | -12.83 | |||||
| ROC (Joel Greenblatt) % | -164.36 | |||||
| ROCE % | -17.4 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 138.77 | |||||
| PB Ratio | 6.38 | |||||
| Price-to-Tangible-Book | 6.39 | |||||
| EV-to-EBIT | -79.11 | |||||
| EV-to-EBITDA | -80.77 | |||||
| EV-to-Revenue | 139.7 | |||||
| EV-to-FCF | -95.57 | |||||
| Price-to-Projected-FCF | 110.89 | |||||
| Price-to-Net-Current-Asset-Value | 7.14 | |||||
| Price-to-Net-Cash | 7.33 | |||||
| Earnings Yield (Greenblatt) % | -1.26 | |||||
| FCF Yield % | -0.9 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zealand Pharma AS Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 367.972 | ||
| EPS (TTM) (kr) | -11.75 | ||
| Beta | 1.02 | ||
| Volatility % | 59.84 | ||
| 14-Day RSI | 56.28 | ||
| 14-Day ATR (kr) | 31.200865 | ||
| 20-Day SMA (kr) | 808.25 | ||
| 12-1 Month Momentum % | 152.13 | ||
| 52-Week Range (kr) | 274.4 - 972 | ||
| Shares Outstanding (Mil) | 70.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zealand Pharma AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zealand Pharma AS Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Zealand Pharma AS Frequently Asked Questions
What is Zealand Pharma AS(OCSE:ZEAL)'s stock price today?
The current price of OCSE:ZEAL is kr845.00. The 52 week high of OCSE:ZEAL is kr972.00 and 52 week low is kr274.40.
When is next earnings date of Zealand Pharma AS(OCSE:ZEAL)?
The next earnings date of Zealand Pharma AS(OCSE:ZEAL) is 2024-11-07.
Does Zealand Pharma AS(OCSE:ZEAL) pay dividends? If so, how much?
Zealand Pharma AS(OCSE:ZEAL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers